SecBot SecBot

SYBX

SYNLOGIC, INC.
OTC· Pharmaceutical Preparations· Inc. DE· CIK 0001527599 Biotech & Drug Discovery
$1.10 +0.00 (+0.00%)
Nov 16 4:00 PM ET · prev $1.10
1 year
−34.9%
from $1.69 · Nov 17
30 days
+2.8%
from $1.07
52-week range
$0.5600–1.69
−35% from high · low Jan 20
Avg volume 20D
6.0K
Nov 11 spike 21.3K
Short interest
2.9K
0.0%
Days to cover
1.0
at average volume
Insider net
$0.00
1 buyer · 0 sellers · 12 mo
New fund stakes
0
Q4 2025 13F · 0 exits
Filing reports
5
analyzed by SecBot
SecBot read MIXED 2 reports · 90 days
Balance 0 bearish · 0 bullish · 2 neutral oldest → newest, height = score
Avg score ·High conf. 2/2

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersMIXED

    No open-market sales.

  • InstitutionsMIXED

    Q4 2025: 1 added (0 new), 0 trimmed or exited.

  • Short sellersSTEADY

    Short interest 0.0% to 2.9K shares. 1.0 days to cover.

  • TrendRANGE

    1% above its 50-day average.

Who's buying

13F· Q4 2025
0
new positions
0
exits
FundMoveSharesValue
RENAISSANCE TECHNOLOGIES LLCDOUBLED85,627$95.9K
RENAISSANCE TECHNOLOGIES LLCADD39,510$65.9K
FMR LLCNEAR_EXIT5,323$9.0K
JPMORGAN CHASE & CONEAR_EXIT1$1.00
RENAISSANCE TECHNOLOGIES LLCTRIM22,310$31.2K
FMR LLCTRIM166,724$248.4K
CITADEL ADVISORS LLCTRIM16,449$24.5K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

Last action Mar 2024
Recent actions
DateFirmActionRating
Mar 20, 2024HC Wainwright & Co.
UPGRADE
UPGRADENeutral
Feb 9, 2024Chardan Capital
DOWNGRADE
DOWNGRADENeutral
Feb 9, 2024Leerink Partners
DOWNGRADE
DOWNGRADEMarket Perform
Feb 9, 2024HC Wainwright & Co.
DOWNGRADE
DOWNGRADESell
Dec 11, 2023Alliance Global Partners
INITIATE
INITIATEBuy

Insider ledger

Form 4
$0
bought · 1 insider
$0
sold · 0 insiders
DateInsiderTypeValue
Jul 27, 2026
New Enterprise Associates 14, L.P.
Director
Jul 27, 2026
BUY2,640,845 sh
Jul 27, 2026
New Enterprise Associates 14, L.P.
Director
Jul 27, 2026
EXPIRED2,640,845 sh

Earnings setup

Estimates
PeriodEPS est.Range30D rev.Revenue
Current QNoneNoneNo data$0.00
Next QNoneNoneNo data$0.00
Current FYNoneNoneNo data$0.00
Next FYNoneNoneNo data$0.00
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent

Short side

FINRA· Oct 30, 2026
2,854
shares short
0.0%
vs prior settlement
1.0
days to cover
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 11, 2026 Earnings calendar
SYBX Q3 2026 Earnings Scheduled · 2026-11-11
Nov 5, 2026 SEC
Caldera Therapeutics, the private biotech merging with Synlogic (SYBX), announced positive Phase 1a data for its lead…
425 · Impact 4/10
Nov 2, 2026 SEC
Caldera Therapeutics, the private biotech merging with Synlogic (SYBX), announced the appointment of Michelle Doig as…
425 · Impact 3/10
Jul 29, 2026 SEC
Synlogic (SYBX) has entered into a definitive merger agreement with Caldera Therapeutics, a private biotech, via a…
425, 8-K · Impact 7/10
Jul 27, 2026 Insider
New Enterprise Associates 14, L.P. bought 2,640,845 shares
Director
Jul 27, 2026 Insider
New Enterprise Associates 14, L.P. disposed of 2,640,845 shares
Director
Dec 31, 2025 Inst.
RENAISSANCE TECHNOLOGIES LLC · DOUBLED
85,627 shares ($95.9K)
Sep 30, 2025 Inst.
RENAISSANCE TECHNOLOGIES LLC · ADD
39,510 shares ($65.9K)

SecBot reports

5 filings · 0 bullish · 2 bearish · 3 neutral
All SYBX filing & press-release reports (5)